In today’s briefing:
- Mani Inc (7730 JP): No Immediate Respite Seen
- Bioer IPO: Currently Holding Strong but Would Growth Rates Sustain Post-COVID?
Mani Inc (7730 JP): No Immediate Respite Seen
- Mani Inc (7730 JP) offers medical devices, which are mainly used in the elective procedures including cataract surgery and dental procedures.
- In FY21, the company missed its guidance for both revenue and operating income by 2% and 5%, respectively, due to higher-than-expected impact of the COVID-19.
- With the rising cases of highly infectious Omicron variant of the COVID-19 in major operating regions, the company is expected to miss or lower its FY22 guidance.
Bioer IPO: Currently Holding Strong but Would Growth Rates Sustain Post-COVID?
- Bioer designs, manufactures and sells three categories of PCR products: instruments, reagents and consumables. With the spread of COVID-19, the company experienced strong growth in revenue and margin improvements.
- The company has filed for an IPO to list its shares on the Hong Kong Stock Exchange and plans to raise proceeds of around US$200m
- Strong growth in Bioer’s revenue over the last two years was predominantly driven by the spread of COVID-19. We are concerned on the company’s ability to maintain its revenues post-COVID.
Before it’s here, it’s on Smartkarma
